Latest Merkel cell cancer Stories

SAN DIEGO, July 11, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has established the University of California San Francisco (UCSF) as the second enrolling site for its Phase II Merkel cell carcinoma clinical trial (OMS-I110). UCSF investigators are actively recruiting patients for this clinical trial. OMS-I110 was initiated at the University...

Radionuclide therapy study shows a novel treatment for basal cell carcinoma can cure patients without requiring hospitalization A customized patch treatment for basal cell carcinoma completely destroys facial tumors without surgery or major radiation therapy in 80 percent of patients studied, say researchers at the Society of Nuclear Medicine's 2012 Annual Meeting. There are two main types of skin cancer:melanoma, which forms deep in the cells that produce pigment in skin, and...

Aspirin and other similar painkillers may help protect against skin cancer, a new study suggests. Published in the online journal CANCER, a peer-reviewed journal of the American Cancer Society, the findings indicate that skin cancer prevention may be added to the benefits of these commonly used medications. Previous studies suggest that taking nonsteroidal anti-inflammatory drugs, or NSAIDs, such as ibuprofen, naproxen and aspirin, as well as a variety of other nonprescription and...

SAN DIEGO, May 29, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, issued the following letter to Shareholders today: (Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO) Dear Shareholder: As we near the mid-point of 2012, OncoSec is successfully executing on its objectives for the year. I want to review the key developments so you can see...

Four years after they discovered the viral roots of a rare skin cancer, researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have now identified a molecule activated by this virus that, in animal studies, could be targeted to selectively kill the tumor cells. The treatment will soon be tested in patients. Merkel cell carcinoma (MCC), a skin cancer that is more common among seniors and those with weakened immune systems, could not be readily...

SAN DIEGO, March 19, 2012 /PRNewswire/ -- OncoSec Medical Incorporated. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Dr. Paul Nghiem, Co-Principal Investigator for OncoSec's Phase II Merkel cell carcinoma study has been invited to chair a special forum session at the 70th Annual American Academy of Dermatology meeting in San Diego, CA, titled, "Merkel Cell...

SAN DIEGO, March 7, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Dr. Shailender Bhatia, Principal Investigator for the company's Phase II Merkel cell carcinoma clinical trial, was featured in a local Seattle news outlet, The Journal Newspaper. (Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO) The article,...

SAN DIEGO, Feb. 13, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for...

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, the University Hospital for Einstein, have found a biomarker in head and neck cancers that can predict whether a patient's tumor will be life threatening. The biomarker is considered particularly promising because it can detect the level of risk immediately following diagnosis. This discovery could become a component of a new test to guide how aggressively those with head and neck tumors...

SAN DIEGO, Jan. 18, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, presented its corporate strategy for 2012 and reported on progress since launch of the company last year at the Biotech Showcase and OneMedForum conferences held January 9-13 in San Francisco, CA. (Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO) "Despite a...